|
Region
|
OR (95% CI)a
|
P-value
|
|---|
|
Diffuse plaques (moderate + frequent vs. no + sparse)
|
|
Amygdala
|
3.34 (1.47–8.99)
|
0.0079
|
|
Hippocampus
|
1.45 (0.81–2.71)
|
0.23
|
|
EC/inferior TCTX
|
2.61 (1.20–6.53)
|
0.025
|
|
Frontal neocortex
|
2.30 (0.63–14.93)
|
0.28
|
|
Neuritic plaques (moderate + frequent vs. no + sparse)
|
|
Amygdala
|
2.84 (1.57–5.44)
|
9.1 × 10
− 4
|
|
Hippocampus
|
2.56 (1.58–4.29)
|
2.2 × 10
− 4
|
|
EC/inferior TCTX
|
4.04 (2.11–8.43)
|
6.6 × 10
− 5
|
|
Frontal neocortex
|
1.88 (0.71–5.92)
|
0.23
|
|
Thal Aβ phase (phase 4 + 5 vs. phase 0 to 3)
|
|
Amygdala
|
2.78 (1.56–5.21)
|
8.5 × 10
− 4
|
|
Hippocampus
|
2.34 (1.44–3.93)
|
8.5 × 10
− 4
|
|
EC/inferior TCTX
|
2.52 (1.41–4.77)
|
0.0029
|
|
Frontal neocortex
|
1.42 (0.53–4.50)
|
0.51
|
|
Braak NFT stage (stage V + VI vs. stage 0 to IV)
|
|
Amygdala
|
3.38 (1.99–5.95)
|
1.3 × 10
− 5
|
|
Hippocampus
|
2.90 (1.86–4.63)
|
4.2 × 10
− 6
|
|
EC/inferior TCTX
|
3.15 (1.86–5.53)
|
3.4 × 10
− 5
|
|
Frontal neocortex
|
1.22 (0.52–3.06)
|
0.66
|
- aOdds ratios were adjusted for sex, age at death, APOE genotype, and the type of TDP-43 antibody
- OR odds ratio, CI confidence interval, EC entorhinal cortex, TCTX temporal cortex, NFT neurofibrillary tangle
- Bold p-value represents the statistical significance
